tropisetron / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   44 Trials   44 Trials   130 News 


123»
  • ||||||||||  tropisetron / Generic mfg.
    Journal:  Studies on the mechanisms of action of MR33317. (Pubmed Central) -  Oct 29, 2024   
    These findings highlight a potential connection between 5-HT3 and NMDA receptors in the pharmacological treatment of inflammatory diseases, such as seizure, warranting further investigation into their combined therapeutic effects. This increase in force of contraction in human atrium by MR33317 was attenuated by 10
  • ||||||||||  Diacomit (stiripentol) / Biocodex, Meiji Seika
    Journal:  Camel FGF21 Protein Enhances FGF21 Signaling and its Targeted Compounds Screening. (Pubmed Central) -  Oct 1, 2024   
    TRO exerted a protective role against HG-caused ARPE-19 cells inflammation, oxidative stress and cell apoptosis by regulating SIRT1/ROCK1 axis, suggesting that TRO might be therapeutic agent for alleviating retinal pigment epithelial cell damage in DR. This study has provided new ideas for developing therapeutic strategies based on FGF21 protein modification and exploring novel disease treatment strategies based on the compounds-protein combination.
  • ||||||||||  tropisetron / Generic mfg.
    Journal:  Zacopride stimulates 5-HT4 serotonin receptors in the human atrium. (Pubmed Central) -  Sep 24, 2024   
    This study has provided new ideas for developing therapeutic strategies based on FGF21 protein modification and exploring novel disease treatment strategies based on the compounds-protein combination. The positive inotropic effect of zacopride in HAP was attenuated by either 10
  • ||||||||||  Rituxan (rituximab) / Roche
    Enrollment change, Trial withdrawal:  Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (clinicaltrials.gov) -  Aug 6, 2024   
    P=N/A,  N=0, Withdrawn, 
    Compounds that function differently from existing antipsychotics may offer novel symptom-specific therapeutic strategies for patients with schizophrenia. N=130 --> 0 | Unknown status --> Withdrawn
  • ||||||||||  Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
    Enrollment closed, Trial primary completion date:  Oral Akynzeo (clinicaltrials.gov) -  Apr 18, 2024   
    P4,  N=414, Active, not recruiting, 
    Registration site: www.chictr.org.cn (ChiCTR2300069994). Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Jul 2024
  • ||||||||||  dexamethasone / Generic mfg., tropisetron / Generic mfg.
    Phase classification:  Efficacy of Three Antiemetics in Preventing Nausea and Vomiting (clinicaltrials.gov) -  Apr 4, 2024   
    P4,  N=200, Completed, 
    Thus, repositioning of tropisetron could represent a promising therapeutic strategy in management of HD. Phase classification: P=N/A --> P4
  • ||||||||||  dexamethasone / Generic mfg., tropisetron / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date:  Efficacy of Three Antiemetics in Preventing Nausea and Vomiting (clinicaltrials.gov) -  Mar 27, 2024   
    P=N/A,  N=200, Completed, 
    Phase classification: P=N/A --> P4 Recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Feb 2023 --> Nov 2023 | Trial primary completion date: Feb 2023 --> Oct 2023
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  HELEN-009: Anti-emetic Prophylaxis With or Without Dexamethasone (clinicaltrials.gov) -  Feb 26, 2024   
    P3,  N=403, Completed, 
    Recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Feb 2023 --> Nov 2023 | Trial primary completion date: Feb 2023 --> Oct 2023 Recruiting --> Completed | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jan 2024 --> Aug 2023
  • ||||||||||  Retrospective data, Journal:  Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis. (Pubmed Central) -  Feb 15, 2024   
    Recruiting --> Completed | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jan 2024 --> Aug 2023 The studies were categorised according to the background regimen: participants were treated with risperidone, mixed antipsychotics or clozapine...The most notable effect sizes (ESs) were observed for the use of tropisetron (standard mean difference:
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer (clinicaltrials.gov) -  Feb 5, 2024   
    P3,  N=116, Completed, 
    The studies were categorised according to the background regimen: participants were treated with risperidone, mixed antipsychotics or clozapine...The most notable effect sizes (ESs) were observed for the use of tropisetron (standard mean difference: Recruiting --> Completed | N=206 --> 116 | Trial completion date: Sep 2024 --> Aug 2023 | Trial primary completion date: Jul 2024 --> Jul 2023
  • ||||||||||  tropisetron / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting (clinicaltrials.gov) -  Oct 23, 2023   
    P4,  N=480, Completed, 
    Individually, all 5-HT3R-As outperformed placebo regarding Y-BOCS total score (granisetron: MD Recruiting --> Completed | Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Feb 2023 --> Jun 2023
  • ||||||||||  glibenclamide / Generic mfg., tropisetron / Generic mfg.
    Preclinical, Journal, IO biomarker:  Tropisetron improved testicular inflammation in the streptozotocin-induced diabetic rats: The role of toll-like receptor 4 (TLR4) and mir146a. (Pubmed Central) -  Mar 14, 2023   
    This study demonstrated that the significant role of tropisetron in lowering testicular inflammation and apoptosis might have been due to the inhibition of the TLR4/IRAK1/TRAF6 signaling pathway and thereby the attenuation of NF-?B and caspase3 expression and inflammatory cytokines. Furthermore, the downregulation of mir146a, as an inflammatory microRNA interacting with TLR4, showed another pathway, through which tropisetron improved diabetes-induced testicular injuries.
  • ||||||||||  ondansetron / Generic mfg., tropisetron / Generic mfg.
    Journal:  Potential Roles of 5-HT3 Receptor Antagonists in Reducing Chemotherapy-Induced Peripheral Neuropathy (CIPN). (Pubmed Central) -  Mar 9, 2023   
    As it was also shown in pre-clinical and clinical studies that various neuropathic pains could be blocked by the 5-HT3 receptor antagonists, we proposed that 5-HT3 receptor antagonists via 5-HT3 receptors may also inhibit of neuropathic pain induced by chemotherapy. Our review suggests that future studies focus more on the 5-HT3 receptor antagonists and their modulation in CIPN to close the gap in the current pharmacotherapy for cancer-related pain.
  • ||||||||||  Emestop (ramosetron hydrochloride) / Samyang Group
    Biomarker, Journal:  The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics. (Pubmed Central) -  Mar 1, 2023   
    Our review suggests that future studies focus more on the 5-HT3 receptor antagonists and their modulation in CIPN to close the gap in the current pharmacotherapy for cancer-related pain. This review highlights that inefficacy of a specific drug in managing PONV could be attributed to specific genetic profiles and patients would possibly benefit from a drug switch.
  • ||||||||||  tropisetron / Generic mfg.
    Retrospective data, Journal:  Effect of preoperative tropisetron treatment on postoperative cognitive function: A retrospective cohort study. (Pubmed Central) -  Jan 4, 2023   
    Multifactorial logistic regression analysis suggested that tropisetron was a protective factor for postoperative cognitive function, with a statistically significant effect (odds ratio [OR] = 5.04, 95% confidence interval [CI] = 1.31-19.4). Preoperative tropisetron exposure significantly reduces the incidence of postoperative cognitive impairment in patients, and it is a protective factor for postoperative cognitive function.
  • ||||||||||  tropisetron / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy:  Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting (clinicaltrials.gov) -  Dec 28, 2022   
    P4,  N=480, Recruiting, 
    Preoperative tropisetron exposure significantly reduces the incidence of postoperative cognitive impairment in patients, and it is a protective factor for postoperative cognitive function. Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023
  • ||||||||||  dexamethasone / Generic mfg., tropisetron / Generic mfg.
    Enrollment open:  Efficacy of Three Antiemetics in Preventing Nausea and Vomiting (clinicaltrials.gov) -  Dec 28, 2022   
    P1,  N=200, Recruiting, 
    Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
    Trial completion date, Trial primary completion date:  Oral Akynzeo (clinicaltrials.gov) -  Nov 9, 2022   
    P4,  N=530, Recruiting, 
    Further studies are needed to evaluate the precise mechanism behind cyclosporine, ondansetron, and tropisetron activities. Trial completion date: Aug 2023 --> Nov 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Acacia Pharma
    Journal:  Prevention of postoperative nausea and vomiting after gynaecological day surgery under remimazolam general anesthesia: a randomized double-blind controlled study. (Pubmed Central) -  Sep 21, 2022   
    These findings suggest that tropisetron attenuates diabetes-induced peripheral nerve injury through its anti-inflammatory and anti-apoptotic effects, and may provide a novel therapeutic strategy to ameliorate the process of peripheral neuropathy in diabetes. Droperidol or tropisetron combined with dexamethasone is superior to dexamethasone alone for the prevention of PONV in the PACU after remimazolam combined with alfentanil anesthesia, with no significant difference in the incidence of PONV in 24 h after surgery.